Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT.

@article{Klotz2015NadirTW,
  title={Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT.},
  author={Laurence H. Klotz and C O'callaghan and Keyue Ding and Paul Toren and David Paul Dearnaley and Celestia S. Higano and Eric Mark Horwitz and Shawn Christopher Malone and Larry Goldenberg and Mary Krystyna Gospodarowicz and Juanita Crook},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2015},
  volume={33 10},
  pages={
          1151-6
        }
}
PURPOSE Three small retrospective studies have suggested that patients undergoing continuous androgen deprivation (CAD) have superior survival and time to progression if lower castrate levels of testosterone (< 0.7 nmol/L) are achieved. Evidence from prospective large studies has been lacking. PATIENTS AND METHODS The PR-7 study randomly assigned patients experiencing biochemical failure after radiation therapy or surgery plus radiation therapy to CAD or intermittent androgen deprivation. The… CONTINUE READING